未知机构：必贝特PCSK9AGT双靶点siRNA获批12期IND持续推荐东吴-20260204

Summary of Key Points from Conference Call Company Overview - The company discussed is 必贝特 (Bebetter), which focuses on innovative drug development, particularly in the field of RNA therapeutics. Industry Insights - The approval of PCSK9/AGT dual-target siRNA for Phase 1/2 IND in China marks a significant milestone in the treatment of mild to moderate hypertension combined with elevated low-density lipoprotein cholesterol (LDL-C) [1] - The global market for hypertension patients is approximately 1.4 billion, with 245 million patients in China, indicating a substantial market opportunity [1] Core Developments - The company utilizes a proprietary GDOC technology platform that features a unique parallel structural design, which is expected to enhance the stability and delivery efficacy of the siRNA [1] - The dual-target approach is positioned to provide synergistic benefits in lowering blood pressure and cholesterol, potentially improving patient adherence to medication regimens [1] Pipeline Highlights - The company has several projects in its pipeline, including: - BEBT-507 for TMPRSS6 in polycythemia vera (Phase 1) - BEBT-701 targeting AGT + PCSK9 for hypertension and hyperlipidemia - BEBT-706 for Lp(a) + PCSK9 in atherosclerotic cardiovascular disease (ACSVD) - BEBT-720 for CIDEB + HSD17B13 in metabolic-associated steatotic liver disease (MASH) - BEBT-758 targeting SNCA for Parkinson's disease - BEBT-756 for APP + Tau in Alzheimer's disease - Additional projects addressing hyperuricemia and gout, renal anemia/CKD, and diabetes [2][3] Strategic Recommendations - Continued focus on the dual-target project and advancements in CNS-targeted delivery and renal delivery systems is recommended for potential breakthroughs in treatment [2]